Call for Abstract

10th World Congress on Biomarkers & Clinical Research, will be organized around the theme “Latest discoveries and innovations in the field of Biomarkers & Clinical Research”

Biomarkers 2017 is comprised of 21 tracks and 16 sessions designed to offer comprehensive sessions that address current issues in Biomarkers 2017.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Growth research is fundamental research into tumor to recognize causes and create methodologies for aversion, analysis, treatment, and cure. Growth investigate ranges from the study of disease transmission, sub-atomic bioscience to the execution of clinical trials to assess and think about utilizations of the different malignancy medicines. These applications incorporate surgery, radiation treatment, chemotherapy, hormone treatment, immunotherapy and consolidated treatment modalities, for example, chemo-radiotherapy. Beginning in the mid-1990s, the accentuation in clinical disease explore moved towards treatments got from biotechnology research, for example, tumor immunotherapy and quality treatment.

A key ingredient in successful entrepreneurship is self-knowledge. Biomarkers-2017 aims to bring together all existing and budding bio entrepreneurs to share experiences and present new innovations and challenges in cancer community. Each year, over a million companies are started in the world with about 5–10 of them classified as high technology companies. Turning ideas into business ventures is tricky and the opportunity-recognition step is critical in new venture creation. This gestalt in the entrepreneur's perception of the relationship between the invention and final product is refined into a business model that describes how the venture will make money or provide an appropriate return to the potential investors. Cancer science is complex and rapidly changing and requires a specialized knowledge to understand the value of the innovation and its competitive position in the industry. This three day community-wide conference will be a highly interactive forum that will bring experts in areas ranging from Biomarkers to signalling pathways to novel therapeutic approaches to the scientific hub.

A case report is an elaborated report of the symptoms, signs, disease diagnosis, treatment, and follow-up of an individual patient usually recorded in medical field. Case reports might comprehend a demographic profile of the patient, but typically mention any unusual or unique occurrences. In this conference case reports on biomarker diagnostics, drug discovery and imaging are discussed in detail in relevance to molecular and cancer biomarkers. Cancer biomarkers conferences are a big platform to study case reports of these in precision.

In the biomarker pipeline, the technologies that will enable the use of biomarkers in drug discovery and development vary depending on the research stage. The second stage, biomarker validation and clinical assay development, depends upon extremely sensitive and specific high-throughput immunoassays. The single greatest challenge in discovering biomarkers with clinical utility is the sensitivity and specificity necessary to determine that a biomarker is truly positive for disease or disease toxicodynamics, and can be used to detect deviations from normal. The molecular biomarkers conferences provide good exposure in drug discovery. Biomarkers have special applications in the areas of translational medicine, clinical development and safety assessment where they are put through several stages of drug discovery, development and validation.

  • Track 4-1Clinical Pharmacology
  • Track 4-2Environmental Pharmacology
  • Track 4-3Pharmacogenomics

Biomarkers are the existing bimolecular and integral indictors of disease condition of biological systems. The techniques used to identify and maximize the expression of biomarkers include RT-PCR genotyping, molecular imaging and dynamics, biochemical  assay and profiling, immunological techniques and chromatographic techniques. A wider approach towards identification of biomarkers lies in the proteomic approach besides utilizing biosensors as a compatible tool for evaluation of biomarker levels in the biological systems. Most of the company’s focus is on generating cost effective durable profiling techniques and equipment to quantify biomarkers within a short span of time. Johnson & Johnson, GlaxoSmithKline Plc., GE Healthcare, Affymetrix Inc.

Biomarkers play a critical role in disease diagnosis and treatment, especially for the early detection of cancer, to enable screening of asymptomatic populations. Recent omics technologies, such as Transcriptomics, genomics and proteomics approaches besides Metabolomics are accelerating the rate of biomarker discovery. The incorporation of techniques like microarray data analysis, computational biology, data mining methods, Transcriptomics and profiling techniques are playing a crucial role in the validation of biomarkers. Since the Human Genome Project was completed in April 2003, genome-wide association studies (GWAS) have contributed toward a greater understanding of the genetic basis of complex diseases and advances in high-throughput technologies. This has enabled researchers to rapidly map the genome of vertebrates, invertebrates and pathogens through cost-effective methods.

The branch of genomics that determines the biological function and complex association of the genes and their products depicts the functional genomics. The measurable degree of these parameters through various processes and equipment inclusive of Next generation sequencing, Personalized genome sequencing and mi-RNA sequencing utilizing cellular entities to predict SNP biomarkers, immuno fluorescent biomarkers, oxidative stress biomarkers, si-RNA and mi-RNA will aid in better understanding of the disease outcome. The cytogenetic biomarkers are a feasible diagnostic tool to detect DNA and chromatin damage.

Disease-related biomarkers give an indication of the probable effect of treatment on patient (risk indicator or predictive biomarkers), if a disease already exists (diagnostic biomarker), or how such a disease may develop in an individual case regardless of the type of treatment (prognostic biomarker). Predictive biomarkers help to assess the most likely response to a particular treatment type, while prognostic markers show the progression of disease with or without treatment, some diseases are:-

  • Autoimmune disease
  • Alzheimer's disease
  • Cardiovascular disease
  • Neurological Disorders
  • Immunological Disorders

Translational prescription regularly alluded to as translational science, (of which it is a frame) is characterized by the European Society for Translational Medicine (EUSTM) as an interdisciplinary branch of the biomedical field bolstered by three primary columns: benchside, bedside and group. The objective of TM is to consolidate disciplines, assets, mastery, and strategies inside these columns to advance upgrades in aversion, analysis, and treatments. As needs be, TM is a very interdisciplinary field, the essential objective of which is to mix resources of different natures inside the individual columns keeping in mind the end goal to enhance the worldwide social insurance framework altogether.

Clinical trials are tests done in clinical research. Such imminent biomedical or behavioral research thinks about on human members are intended to answer particular inquiries regarding biomedical or behavioral mediations, including new medications, (for example, novel antibodies, drugs, dietary decisions, dietary supplements, and medicinal gadgets) and known intercessions that warrant additionally study and examination. Clinical trials produce information on security and viability.

  • Track 10-1Conducts of Clinical Trials

Clinical research is a branch of social insurance science that decides the wellbeing and adequacy (viability) of solutions, gadgets, analytic items and treatment regimens expected for human utilize. These might be utilized for counteractive action, treatment, finding or for calming side effects of a sickness. Clinical research is unique in relation to clinical practice. In clinical practice built up medicines are utilized, while in clinical research confirmation is gathered to set up a treatment.

  • Track 11-1Innovations in Pre-clinical Research
  • Track 11-2Design of Clinical Studies

A biomarker, or natural marker, for the most part alludes to a quantifiable pointer of some organic state or condition. The term is additionally infrequently used to allude to a substance the nearness of which demonstrates the presence of a living being. Encourage, life structures are known to shed one of kind chemicals, including DNA, into the earth as proof of their nearness in a specific area. Biomarkers are regularly measured and assessed to look at ordinary natural procedures, pathogenic procedures, or pharmacologic reactions to a restorative mediation. Biomarkers are utilized as a part of numerous logical fields.

Recently there has been enhanced and advanced biomedical technology such as high-throughput molecular imaging and microarrays to monitor SNPs, gene and protein expressions, to provide exhaustive situations for individuals. The biological and medical status from such data sets, which are viewed as biomarkers in a wide sense to help to do identification, association, and prediction studies for phenotypes such as cancer subtypes, prognosis, treatment responsiveness, and adverse reactions for personalized medicine.

As a rule, biomarker inquires about takes after a continuum that starts with disclosure and continues through approval to the possible execution of biomarkers in a clinical setting. Biomarker disclosure requires high certainty recognizable proof of biomarker applicants with concurrent quantitation data to demonstrate which proteins are changing to a factually significant degree in light of infection. Biomarker competitors distinguished in disclosure should be approved utilizing bigger example sets covering an expansive segment of patient companions. To maintain a strategic distance from a potential bottleneck connected with taking countless to approval, a confirmation step is utilized to screen potential biomarkers to guarantee that lone the most noteworthy quality leads from the disclosure stage are taken into the exorbitant approval arrange. The check arranges requires a high throughput work process with at least specimen planning that gives both high specificity and affectability. Also, the confirmation stage can affirm that a specific philosophy is reasonable to be utilized as a part of the approval stage.

  • Track 14-1Mass spectrometry based biomarker discovery, verification, and validation
  • Track 14-2Protein Biomarker Discovery & Validation

Biomarkers are the trademark natural quantifiable indictors for the different issue if happening in strange levels. These are utilized as quantitative elements for neurological issue, hereditary scatters, metabolic disarranges, cardiovascular clutters and natural mistakes. The present time is concentrating on the tumor examine using biomarkers as indictor of infection conditions. The lung disease biomarkers and biomarkers for bosom malignancy are comprehensive of qualities, chemicals, proteins and cell surface entitles. Enrolling a compound yearly development rate of 14.60% from 2011 to 2018, the market for oncology biomarkers was esteemed at $13.16 billion in 2011 and is relied upon to be worth $29.78 billion in 2018.Biomarkers are additionally utilized as a part of diagnosing and treating different illnesses and scatters like Neurological issue, Genetic issue, Metabolic issue, Cardiac issue, Inborn blunders, Lung disease and Breast malignancy.

One imperative part of the part of Pathology in the assessment of bosom malignancy is biomarker trying, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

  • Track 16-1Molecular Pathology
  • Track 16-2Clinical Pathology

The part of Biomarkers in medication revelation and advancement is to comprehend the pathophysiology of ailment. Biomarkers can be a clinical instrument for medication disclosure and improvement by affirming the adequacy and security to the correct patient. Biomarkers can be utilized as a part of comprehension the instrument of medication.

The Biomarkers discovers its important application in the field of Clinical innovative work by contextual investigation and information administration as obvious through Biomarker meetings. The Bioethics and protected innovation right builds up the standards and standard of direct of theory concerning clinical approval of biomarkers. The fuse of biomarker in clinical trials for different illness conditions will advance a legitimate indicative and remedial approach using even the medicinal gadgets to recognize clinical biomarkers. Right now this is the blasting business. A large portion of the presumed associations like Pfizer, Parexel and Quintiles are into clinical innovative work. The organizations, doctor's facilities and clinical research associations are the problem areas for directing clinical research with its development rate expanding exponentially by an expected 75B$ by 2016.In clinical innovative work, clinical biomarkers are utilized as a part of contextual analysis and information administration, clinical trials and in therapeutic gadgets.

Disease immunotherapy is the utilization of the safe framework to treat tumor. Immunotherapies can be ordered as dynamic, uninvolved or half and half. These methodologies abuse the way that growth cells frequently have atoms on their surface that can be distinguished by the resistant framework, known as tumor-related antigens, they are regularly proteins or different macromolecules (e.g. sugars).

Dynamic immunotherapy guides the resistant framework to assault tumor cells by focusing on TAAs. Latent immunotherapies upgrade existing against tumor reactions and incorporate the utilization of monoclonal antibodies, lymphocytes and cytokines.

  • Track 19-1Personalized Immunotherapy
  • Track 19-2Companion Diagnostics For Immunotherapy
  • Track 19-3Biomarkers to guide Immunotherapy
  • Track 19-4Clinical Trials for Cancer Immunotherapy

A biomarker can be anything that can be precisely measured as a pointer of ordinary organic working, pathogenic ways or a medication reaction to a restorative medication intercession. Atomic biomarkers are the biomarkers for the most part in sub-atomic frame. Atomic biomarkers partake in different purposes, including illness analysis and visualization, forecast and computation of treatment reaction, and wellbeing assessment. The atomic biomarkers are only being created and approved to be utilized as a part of medication improvement, and used to bolster endorsement of medication items.

  • Track 20-1Molecular Biomarkers Discovery

Growth (Cancer) biomarkers are utilized to distinguish the characteristic course of a tumour and are utilized to evaluate odds of creating disease. Biomarkers in growth screening assume an essential part in tumour identification and hazard evaluation to lessen malignancy passing’s. Tumour biomarkers are utilized to distinguish malignancy advancement and movement. Uterine cervical growth, endometrial disease, trophoblastic neoplasms and ovarian tumour are gynaecologic malignancies for which tumour markers are in clinical utilize. Viable disease biomarkers are utilized to decrease malignancy death rates by encouraging determination of tumours at early stages. Tumour biomarkers can likewise be utilized as a part of analysis, hazard evaluation and repeat of malignancy.

Types of cancer biomarkers

  • Uses of biomarkers in cancer research
  • Lung cancer biomarkers
  • Prostate cancer biomarkers
  • Breast cancer biomarkers
  • Advanced biomarkers for Cancer
  • Track 21-1Cancer Bioinformatics